{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T19:27:02Z","timestamp":1770751622248,"version":"3.50.0"},"publisher-location":"Chichester, UK","reference-count":117,"publisher":"John Wiley & Sons, Ltd","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1002\/14651858.cd005011.pub2","type":"reference-entry","created":{"date-parts":[[2007,4,3]],"date-time":"2007-04-03T23:45:17Z","timestamp":1175643917000},"source":"Crossref","is-referenced-by-count":10,"title":["Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia"],"prefix":"10.1002","author":[{"given":"Yulia","family":"Lin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Stanworth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janet","family":"Birchall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolyn","family":"Doree","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris","family":"Hyde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,4,18]]},"reference":[{"key":"10.1002\/14651858.CD005011.pub2-BIB1|cit1","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/01.TA.0000171453.37949.B7","article-title":"Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized placebo-controlled double blind clinical trials","volume":"59","author":"Boffard","year":"2005","journal-title":"Journal of Trauma"},{"key":"10.1002\/14651858.CD005011.pub2-BIB2|cit2","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/01.TA.0000171453.37949.B7","article-title":"Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized placebo-controlled double blind clinical trials","volume":"59","author":"Boffard","year":"2005","journal-title":"Journal of Trauma"},{"key":"10.1002\/14651858.CD005011.pub2-BIB3|cit3","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1053\/j.gastro.2004.07.015","article-title":"Recombinant factor VIIa for upper gastrointestinal bleeding patients with cirrhosis: a randomized, double-blind trial","volume":"127","author":"Bosch","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD005011.pub2-BIB4|cit4","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1002\/hep.22216","article-title":"Recombinant factor VIIa for variceal bleeding in patients with advanced cirrhosis: a randomized, controlled trial","volume":"47","author":"Bosch","year":"2008","journal-title":"Hepatology"},{"issue":"8","key":"10.1002\/14651858.CD005011.pub2-BIB5|cit5","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1097\/01.mbc.0000186837.78432.2f","article-title":"Control of bleeding in children with Dengue hemorrhagic fever using recombinant activated factor VII: a randomized, double-blind, placebo-controlled study","volume":"16","author":"Chuansumrit","year":"2005","journal-title":"Blood Coagulation & Fibrinolysis"},{"issue":"Suppl. 33","key":"10.1002\/14651858.CD005011.pub2-BIB6|cit6","first-page":"2","article-title":"A pilot double blind randomized placebo-controlled trial of the use of recombinant factor VIIa (rf VIIa) in high transfusion risk cardiac surgery","volume":"21","author":"Diprose","year":"2005","journal-title":"European Journal of Anaesthesiology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD005011.pub2-BIB7|cit7","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1097\/00001721-200405001-00007","article-title":"Recombinant activated factor VII in cardiac surgery","volume":"15","author":"Herbertson","year":"2004","journal-title":"Blood Coagulation & Fibrinolysis"},{"issue":"5","key":"10.1002\/14651858.CD005011.pub2-BIB8|cit8","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/01.mbc.0000233369.03358.c1","article-title":"Elective administration in infants of low-dose recombinant activated factor VII (rFVIIa) in cardiopulmonary bypass surgery for congenital heart disease does not shorten time to chest closure or reduce blood loss and need for transfusions: a randomized, double-blind, parallel group, placebo-controlled study of rFVIIa and standard haemostatic replacement therapy versus standard haemostatic replacement therapy","volume":"17","author":"Ekert","year":"2006","journal-title":"Blood Coagulation & Fibrinolysis"},{"issue":"1","key":"10.1002\/14651858.CD005011.pub2-BIB9|cit9","first-page":"10","article-title":"Prophylactic administration of recombinant activated factor VII in coronary revascularization surgery","volume":"13","author":"Essam","year":"2007","journal-title":"Internet Journal of Anesthesiology"},{"issue":"2","key":"10.1002\/14651858.CD005011.pub2-BIB10|cit10","first-page":"112","article-title":"Novel applications of recombinant factor VIIa: the effect of the administration of recombinant activated factor VII on perioperative blood loss in patients undergoing transabdominal retropubic prostatectomy: the PROSE study","volume":"28","author":"Friederich","year":"2001","journal-title":"Infusionstherapie und Transfusionsmedizin"},{"issue":"suppl 1","key":"10.1002\/14651858.CD005011.pub2-BIB11|cit11","doi-asserted-by":"crossref","first-page":"S129","DOI":"10.1097\/00001721-200004001-00024","article-title":"The effect of the administration of recombinant activated factor VII on perioperative blood loss in patients undergoing transabdominal retropubic prostatectomy: the PROSE study","volume":"11","author":"Friederich","year":"2000","journal-title":"Blood Coagulation & Fibrinolysis"},{"issue":"9353","key":"10.1002\/14651858.CD005011.pub2-BIB12|cit12","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0140-6736(03)12268-4","article-title":"Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomised trial","volume":"361","author":"Friederich","year":"2003","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD005011.pub2-BIB13|cit13","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1053\/gast.2002.34164","article-title":"Safety and efficacy of recombinant factor VIIa in patients with liver disease undergoing laparoscopic liver biopsy","volume":"123","author":"Jeffers","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD005011.pub2-BIB14|cit14","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.burns.2006.08.010","article-title":"Recombinant FVIIa decreases perioperative blood transfusion requirement in burn patients undergoing excision and skin grafting - results of a single centre pilot study","volume":"33","author":"Johansson","year":"2007","journal-title":"Burns"},{"key":"10.1002\/14651858.CD005011.pub2-BIB15|cit15","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/00000542-200502000-00006","article-title":"Recombinant coagulation factor VIIa in major liver resection: a randomized, placebo-controlled, double-blind clinical trial","volume":"102","author":"Lodge","year":"2005","journal-title":"Anesthesiology"},{"issue":"suppl 1","key":"10.1002\/14651858.CD005011.pub2-BIB16|cit16","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1053\/j.seminhematol.2003.11.014","article-title":"Hemostasis in liver resection surgery","volume":"41","author":"Lodge","year":"2004","journal-title":"Seminars in Hematology"},{"issue":"8","key":"10.1002\/14651858.CD005011.pub2-BIB17|cit17","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1002\/lt.20470","article-title":"Efficacy and safety of repeated perioperative doses of recombinant factor VIIa in liver transplantation","volume":"11","author":"Lodge","year":"2005","journal-title":"Liver Transplantation"},{"issue":"suppl 1","key":"10.1002\/14651858.CD005011.pub2-BIB18|cit18","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1053\/j.seminhematol.2003.11.014","article-title":"Hemostasis in liver resection surgery","volume":"41","author":"Lodge","year":"2004","journal-title":"Seminars in Hematology"},{"key":"10.1002\/14651858.CD005011.pub2-BIB19|cit19","first-page":"1110","article-title":"Effect of recombinant activated factor VIIa on early recovery of patients undergoing cardiac valve replacement under cardiopulmonary bypass: a randomized double-blind placebo-controlled trial","volume":"27","author":"Ma","year":"2006","journal-title":"Academic Journal of Second Military Medical University"},{"key":"10.1002\/14651858.CD005011.pub2-BIB21|cit20","doi-asserted-by":"crossref","first-page":"S235","DOI":"10.1007\/s00134-002-1470-8","article-title":"Intracerebral hemorrhage: natural history and rationale of ultra-early hemostatic therapy","volume":"28","author":"Mayer","year":"2002","journal-title":"Intensive Care Medicine"},{"key":"10.1002\/14651858.CD005011.pub2-BIB20|cit21","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1056\/NEJMoa042991","article-title":"Recombinant activated factor VII for acute intracerebral hemorrhage","volume":"352","author":"Mayer","year":"2005","journal-title":"New England Journal of Medicine"},{"issue":"suppl 1","key":"10.1002\/14651858.CD005011.pub2-BIB22|cit22","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1097\/00001721-200004001-00022","article-title":"Potential role of NovoSeven in the prevention of rebleeding following aneurysmal subarachnoid haemorrhage","volume":"11","author":"Pickard","year":"2000","journal-title":"Blood Coagulation & Fibrinolysis"},{"key":"10.1002\/14651858.CD005011.pub2-BIB24|cit23","doi-asserted-by":"crossref","first-page":"S235","DOI":"10.1007\/s00134-002-1470-8","article-title":"Intracerebral hemorrhage: natural history and rationale of ultra-early hemostatic therapy","volume":"28","author":"Mayer","year":"2002","journal-title":"Intensive Care Medicine"},{"key":"10.1002\/14651858.CD005011.pub2-BIB23|cit24","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1161\/01.STR.0000149628.80251.b8","article-title":"Safety and feasibility of recombinant factor VIIa for acute intracerebral hemorrhage","volume":"36","author":"Mayer","year":"2005","journal-title":"Stroke"},{"issue":"suppl 1","key":"10.1002\/14651858.CD005011.pub2-BIB25|cit25","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1097\/00001721-200004001-00022","article-title":"Potential role of NovoSeven in the prevention of rebleeding following aneurysmal subarachnoid haemorrhage","volume":"11","author":"Pickard","year":"2000","journal-title":"Blood Coagulation & Fibrinolysis"},{"key":"10.1002\/14651858.CD005011.pub2-BIB26|cit26","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1385\/NCC:4:3:206","article-title":"Recombinant activated factor VII for acute intracerebral hemorrhage: US phase IIA trial","volume":"4","author":"Mayer","year":"2006","journal-title":"Neurocritical Care"},{"issue":"20","key":"10.1002\/14651858.CD005011.pub2-BIB27|cit27","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1056\/NEJMoa0707534","article-title":"Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage","volume":"358","author":"Mayer","year":"2008","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD005011.pub2-BIB28|cit28","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1227\/01.neu.0000316898.78371.74","article-title":"Recombinant factor VIIA in traumatic intracerebral hemorrhage: results of a dose-escalation clinical trial","volume":"62","author":"Narayan","year":"2008","journal-title":"Neurosurgery"},{"key":"10.1002\/14651858.CD005011.pub2-BIB29|cit29","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/S0268-960X(03)90001-4","article-title":"Haemopoietic stem cell transplants: the impact of haemorrhagic complications","volume":"17","author":"Bacigalupo","year":"2003","journal-title":"Blood Reviews"},{"issue":"9","key":"10.1002\/14651858.CD005011.pub2-BIB30|cit30","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1111\/j.1538-7836.2005.01523.x","article-title":"Recombinant activated factor VII in treatment of bleeding complications following hematopoietic stem cell transplantation","volume":"3","author":"Pihusch","year":"2005","journal-title":"Journal of Thrombosis & Haemostasis"},{"issue":"8","key":"10.1002\/14651858.CD005011.pub2-BIB31|cit31","first-page":"896","article-title":"Safety and efficacy of single bolus dose of recombinant factor VIIa in patients undergoing orthotopic liver transplantation: a randomized multi-centre study","volume":"11","author":"Planinsic","year":"2002","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD005011.pub2-BIB32|cit32","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1016\/j.transproceed.2007.05.062","article-title":"Activated recombinant factor VII in orthotopic liver transplantation","volume":"39","author":"Pugliese","year":"2007","journal-title":"Transplantation Proceedings"},{"key":"10.1002\/14651858.CD005011.pub2-BIB33|cit33","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1093\/bja\/aei102","article-title":"Use of activated recombinant coagulation factor VII in patients undergoing reconstruction surgery for traumatic fracture of pelvis and acetabulum: a double-blind randomized, placebo-controlled trial","volume":"94","author":"Raobaikady","year":"2005","journal-title":"British Journal of Anaesthesia"},{"key":"10.1002\/14651858.CD005011.pub2-BIB34|cit34","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1097\/BRS.0b013e3181557d45","article-title":"Recombinant activated factor VII in spinal surgery: a multicenter, randomized, double-blind, placebo-controlled, dose-escalation trial","volume":"32","author":"Sachs","year":"2007","journal-title":"Spine"},{"key":"10.1002\/14651858.CD005011.pub2-BIB35|cit35","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.amjsurg.2005.10.019","article-title":"Safety and hemostatic effect of recombinant activated factor VIIa in cirrhotic patients undergoing partial hepatectomy: a multicenter, randomized, double-blind, placebo-controlled trial","volume":"191","author":"Shao","year":"2006","journal-title":"American Journal of Surgery"},{"issue":"12","key":"10.1002\/14651858.CD005011.pub2-BIB36|cit36","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1038\/sj.bmt.1705535","article-title":"Pilot study to test the efficacy and safety of activated recombinant factor VII (NovoSeven) in the treatment of refractory hemorrhagic cystitis following high-dose chemotherapy","volume":"38","author":"Ashrani","year":"2006","journal-title":"Bone Marrow Transplantation"},{"issue":"20","key":"10.1002\/14651858.CD005011.pub2-BIB37|cit37","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1161\/01.CIR.0000038501.87442.02","article-title":"Ability of recombinant factor VIIa to reverses the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers","volume":"106","author":"Bijsterveld","year":"2002","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD005011.pub2-BIB38|cit38","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1365-2141.2003.04811.x","article-title":"Recombinant factor VIIa reverses the anticoagulant effect of the long-acting pentasaccharide idraparinux in healthy volunteers","volume":"124","author":"Bijsterveld","year":"2004","journal-title":"British Journal of Haematology"},{"issue":"5","key":"10.1002\/14651858.CD005011.pub2-BIB39|cit39","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1365-2516.2007.01516.x","article-title":"A randomized, double-blind trial demonstrating bioequivalence of the current recombinant activated factor VII formulation and a new robust 25 degrees C stable formulation","volume":"13","author":"Bysted","year":"2007","journal-title":"Haemophilia"},{"key":"10.1002\/14651858.CD005011.pub2-BIB40|cit40","first-page":"1","article-title":"Safety of activated recombinant factor VII in acute intracerebral hemorrhage: results of two multi-center placebo-controlled trials","volume":"34","author":"Davis","year":"2004","journal-title":"Internal Medicine Journal"},{"issue":"2-3","key":"10.1002\/14651858.CD005011.pub2-BIB41|cit41","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1159\/000104481","article-title":"Impact of recombinant activated factor VII on health-related quality of life after intracerebral hemorrhage","volume":"23","author":"Diringer","year":"2007","journal-title":"Cerebrovascular Diseases (Basel Switzerland)"},{"key":"10.1002\/14651858.CD005011.pub2-BIB42|cit42","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/01.mbc.0000169218.15926.34","article-title":"A study of the pharmacokinetics and safety of recombinant activated factor VII in healthy Caucasian and Japanese subjects","volume":"16","author":"Fridberg","year":"2005","journal-title":"Blood Coagulation and Fibrinolysis"},{"key":"10.1002\/14651858.CD005011.pub2-BIB43|cit43","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1067\/mcp.2002.127740","article-title":"Pharmacodynamics of active site-inhibited factor VIIa in endotoxin-induced coagulation in humans","volume":"72","author":"Jilma","year":"2002","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"3","key":"10.1002\/14651858.CD005011.pub2-BIB44|cit44","first-page":"285","article-title":"The use of recombinant coagulation factor VIIa in patients undergoing surgical correction of scoliosis with the C-D method","volume":"7","author":"Kolban","year":"2005","journal-title":"Ortopedia Traumatologia Rehabilitacja"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD005011.pub2-BIB45|cit45","first-page":"94","article-title":"Use of small doses of recombinant factor VIIa during scoliosis surgery","volume":"86 B.C.","author":"Macieji","year":"2004","journal-title":"Journal of Bone and Joint Surgery (Proceedings)"},{"issue":"7","key":"10.1002\/14651858.CD005011.pub2-BIB46|cit46","doi-asserted-by":"crossref","first-page":"E63","DOI":"10.1161\/STROKEAHA.107.484493","article-title":"rFVII for pediatric acute intracranial hemorrhage (15)","volume":"38","author":"Perez","year":"2007","journal-title":"Stroke"},{"issue":"4","key":"10.1002\/14651858.CD005011.pub2-BIB47|cit47","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.ijoa.2007.06.001","article-title":"Recombinant factor VIIa should be used in massive obstetric haemorrhage","volume":"16","author":"Plaat","year":"2007","journal-title":"International Journal of Obstetric Anesthesia"},{"issue":"5","key":"10.1002\/14651858.CD005011.pub2-BIB48|cit48","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1093\/bja\/aem076","article-title":"Predicting response to recombinant factor VIIa in non-haemophilia patients with severe haemorrhage (1)","volume":"98","author":"Pugh","year":"2007","journal-title":"British Journal of Anaesthesia"},{"issue":"4","key":"10.1002\/14651858.CD005011.pub2-BIB49|cit49","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.ijoa.2007.06.002","article-title":"Recombinant factor VIIa should be used in massive obstetric haemorrhage","volume":"16","author":"Velde","year":"2007","journal-title":"International Journal of Obstetric Anesthesia"},{"issue":"11","key":"10.1002\/14651858.CD005011.pub2-BIB50|cit50","first-page":"812a","article-title":"Recombinant factor VIIa reverses the anticoagulant effect of the long-standing anticoagulant idraparinux in healthy volunteers","volume":"102","author":"Vink","year":"2004","journal-title":"Blood"},{"issue":"6","key":"10.1002\/14651858.CD005011.pub2-BIB51|cit51","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1160\/TH03-09-0605","article-title":"Effect of recombinant factor VIIa on melagatran-induced inhibition of thrombin generation and platelet activation in healthy volunteers","volume":"91","author":"Woltz","year":"2004","journal-title":"Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD005011.pub2-BIB52|cit52","unstructured":"Arai M Factor VIIa: Safety of Eptacog Alfa (activated) (genetical recombination) on adverse events and serious adverse events in patients with acute intracerebral haemorrhage ClinicalTrials.gov 2005"},{"key":"10.1002\/14651858.CD005011.pub2-BIB53|cit53","unstructured":"Flaherty ML Jauch EC The Spot sign for predicting and treating intracerebral hemorrhage growth study Clinicaltrials.gov 2008"},{"key":"10.1002\/14651858.CD005011.pub2-BIB54|cit54","unstructured":"Gajewski JL Vogelsang G Key N Goodnough L A multi-center, randomized, double-blind, parallel groups, placebo-controlled trial on efficacy and safety of activated recombinant factor VII (rFVIIa\/NovoSeven) in the treatment of bleeding in patients following hematopoietic stem cell transplantation (HSCT) Novo Nordisk Clinical Trial ID: F7SCT-1485 2005"},{"key":"10.1002\/14651858.CD005011.pub2-BIB55|cit55","unstructured":"Gaspar-Blaudschun B A multicentre-randomised, double-blind, placebo-controlled, dose escalation trial on safety and efficacy of activated recombinant factor VII (rFVIIa\/NovoSeven\u00ae) in the treatment of post-operative bleeding in patients following cardiac surgery requiring cardiopulmonary bypass Clinicaltrials.gov 2004"},{"key":"10.1002\/14651858.CD005011.pub2-BIB56|cit56","first-page":"1259","article-title":"The safety and efficacy of recombinant activated factor VII for the treatment of bleeding following cardiac surgery: a multinational randomized, placebo-controlled trial","volume":"118","author":"Sellke","year":"2008","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD005011.pub2-BIB57|cit57","unstructured":"Gris JC rhuFVIIa in post-partum hemorrhage ClinicalTrials.gov 2006"},{"key":"10.1002\/14651858.CD005011.pub2-BIB58|cit58","unstructured":"Imberti R Efficacy and safety of factor VIIa (Eptacog Alfa) on rebleeding after surgery for spontaneous supratentorial intracerebral hemorrhage. A randomized, controlled, open-label, investigator-blinded pilot study ClinicalTrials.gov 2005"},{"key":"10.1002\/14651858.CD005011.pub2-BIB59|cit59","doi-asserted-by":"crossref","unstructured":"Iorio A Randomized, open, prospective, multicenter pilot study to evaluate the efficacy and safety of activated recombinant factor VII in acute intracerebral haemorrhage in patients treated with oral anticoagulants or antiplatelets agents ClinicalTrials.gov 2006","DOI":"10.1111\/j.1538-7836.2007.tb01920.x"},{"key":"10.1002\/14651858.CD005011.pub2-BIB60|cit60","unstructured":"Kelleher A A multi-centre, randomised, double-blind, placebo-controlled, dose-escalation trial of safety and efficacy of activated recombinant factor VII (Rfv11a\/NovoSeven) in the treatment of post-operative bleeding in patients following cardiac surgery requiring cardiopulmonary bypass http:\/\/www2.rbht.nhs.uk\/research\/projects"},{"key":"10.1002\/14651858.CD005011.pub2-BIB61|cit61","unstructured":"McCall P Poustie S \"Salvage use\" of recombinant activated factor VII after inadequate haemostatic response to conventional therapy in complex cardiac surgery - a randomised placebo-controlled trial ClinicalTrials.gov 2005"},{"key":"10.1002\/14651858.CD005011.pub2-BIB62|cit62","unstructured":"Molter NC Park MS Frail EA Effect of recombinant coagulation factor VIIa on peri-operative blood loss in patients undergoing major burn excision and grafting ClinicalTrials.gov 2005"},{"key":"10.1002\/14651858.CD005011.pub2-BIB63|cit63","unstructured":"Ng C Use of recombinant activated factor seven (FVII) in bleeding ECMO patients post cardiac surgery. Randomised prospective study National Research Register 2005"},{"key":"10.1002\/14651858.CD005011.pub2-BIB64|cit64","unstructured":"Tortella B A multi-center randomized double-blind parallel group placebo controlled trial to evaluate the efficacy and safety of rFVIIa in the treatment of refractory bleeding in severely injured trauma patients Clinicaltrials.gov 2006"},{"issue":"5","key":"10.1002\/14651858.CD005011.pub2-BIB65|cit65","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1093\/bja\/aei094","article-title":"Recombinant factor VIIa for life-threatening post-partum haemorrhage","volume":"94","author":"Ahonen","year":"2005","journal-title":"British Journal of Anaesthesia"},{"key":"10.1002\/14651858.CD005011.pub2-BIB66|cit66","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.tmrv.2008.02.007","article-title":"Evidence for the use of recombinant factor VIIa in the prevention and treatment of bleeding in patients without hemophilia","volume":"22","author":"Birchall","year":"2008","journal-title":"Transfusion Medicine Reviews"},{"key":"10.1002\/14651858.CD005011.pub2-BIB67|cit67","unstructured":"Brun NC Skolnick B Treatment with recombinant factor VIIa in patients with acute intracerebral haemorrhage by reducing hematoma growth ClinicalTrials.gov 2005"},{"issue":"1","key":"10.1002\/14651858.CD005011.pub2-BIB68|cit68","first-page":"364","article-title":"Mechanism of factor VIIa-dependent coagulation in hemophilia blood (Comment)","volume":"100","author":"Butenas","year":"2002","journal-title":"Blood"},{"key":"10.1002\/14651858.CD005011.pub2-BIB69|cit69","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1365-2516.2007.01516.x","article-title":"A randomized, double-blind trial demonstrating bioequivalence of the current recombinant activated factor VII formulation and a new robust 25\u00b0C stable formulation","volume":"13","author":"Bysted","year":"2007","journal-title":"Haemophilia"},{"key":"10.1002\/14651858.CD005011.pub2-BIB70|cit70","unstructured":"Canadian Blood Services Correspondence 2009"},{"key":"10.1002\/14651858.CD005011.pub2-BIB71|cit71","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1212\/01.wnl.0000208408.98482.99","article-title":"Hematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhage","volume":"66","author":"Davis","year":"2006","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD005011.pub2-BIB72|cit72","unstructured":"Della Corte F Efficacy and safety of factor VIIa on rebleeding after surgery for spontaneous intracerebral hemorhage (ICH) Clinical Trials.gov 2006"},{"key":"10.1002\/14651858.CD005011.pub2-BIB73|cit73","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1161\/STROKEAHA.107.493601","article-title":"Risk of thromboembolic events in controlled trials of rFVIIa in spontaneous intracerebral hemorrhage","volume":"39","author":"Diringer","year":"2008","journal-title":"Stroke"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD005011.pub2-BIB74|cit74","doi-asserted-by":"crossref","first-page":"S248","DOI":"10.1007\/s00134-002-1472-6","article-title":"Ongoing NovoSeven trials","volume":"28","author":"Erhardtsen","year":"2002","journal-title":"Intensive Care Medicine"},{"key":"10.1002\/14651858.CD005011.pub2-BIB75|cit75","unstructured":"Fabricius S Use of NovoSeven in active variceal bleeding ClinicalTrials.gov 2006"},{"key":"10.1002\/14651858.CD005011.pub2-BIB76|cit76","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/sj.bmt.1705670","article-title":"The potential role of recombinant activated FVII in the management of critical hemato-oncological bleeding: a systematic review","volume":"39","author":"Franchini","year":"2007","journal-title":"Bone Marrow Transplantation"},{"key":"10.1002\/14651858.CD005011.pub2-BIB77|cit77","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1097\/MBC.0b013e32822d2a3c","article-title":"Potential role of recombinant activated factor VII for the treatment of severe bleeding associated with disseminated intravascular coagulation: a systematic review","volume":"18","author":"Franchini","year":"2007","journal-title":"Blood Coagulation & Fibrinolysis"},{"key":"10.1002\/14651858.CD005011.pub2-BIB78|cit78","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1055\/s-2008-1066022","article-title":"A critical review on the use of recombinant factor VIIa in life-threatening obstetric postpartum hemorrhage","volume":"34","author":"Franchini","year":"2008","journal-title":"Seminars in Thrombosis and Hemostasis"},{"key":"10.1002\/14651858.CD005011.pub2-BIB79|cit79","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/MBC.0b013e32830496a7","article-title":"The use of recombinant factor VIIa in liver diseases","volume":"19","author":"Franchini","year":"2008","journal-title":"Blood Coagulation and Fibrinolysis"},{"key":"10.1002\/14651858.CD005011.pub2-BIB80|cit80","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1111\/j.1537-2995.2004.04052.x","article-title":"Transfusion medicine service policies for recombinant factor VIIa administration","volume":"44","author":"Goodnough","year":"2004","journal-title":"Transfusion"},{"issue":"1","key":"10.1002\/14651858.CD005011.pub2-BIB81|cit81","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/00001721-200301000-00021","article-title":"Recombinant factor VIIa in preterm neonates with prolonged prothrombin time","volume":"14","author":"Greisen","year":"2003","journal-title":"Blood Coagulation & Fibrinolysis"},{"key":"10.1002\/14651858.CD005011.pub2-BIB82|cit82","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.athoracsur.2008.05.013","article-title":"Efficacy and safety of recombinant activated factor VII to control bleeding in nonhemophiliac patients: a review of 17 randomized controlled trials","volume":"86","author":"Hardy","year":"2008","journal-title":"Annals of Thoracic Surgery"},{"key":"10.1002\/14651858.CD005011.pub2-BIB83|cit83","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/j.1365-2141.2006.06087.x","article-title":"The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation","volume":"133","author":"Hay","year":"2006","journal-title":"British Journal of Haematology"},{"issue":"1","key":"10.1002\/14651858.CD005011.pub2-BIB84|cit84","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1046\/j.1537-2995.2002.00017.x","article-title":"Potential role for rVIIa in transfusion medicine","volume":"42","author":"Hedner","year":"2002","journal-title":"Transfusion"},{"issue":"3","key":"10.1002\/14651858.CD005011.pub2-BIB85|cit85","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1097\/00007890-200102150-00011","article-title":"Reduced transfusion requirements by recombinant factor VIIa in orthotopic liver transplantation: a pilot study","volume":"71","author":"Hendriks","year":"2001","journal-title":"Transplantation"},{"key":"10.1002\/14651858.CD005011.pub2-BIB86|cit86","doi-asserted-by":"crossref","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions 5.0.1 [updated September 2008] Available from www.cochrane-handbook.org 2008","DOI":"10.1002\/9780470712184"},{"key":"10.1002\/14651858.CD005011.pub2-BIB87|cit87","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/SLA.0b013e318176c4ec","article-title":"Use of recombinant activated factor VII in patients without hemophilia: a meta-analysis of randomized control trials","volume":"248","author":"Hsia","year":"2008","journal-title":"Annals of Surgery"},{"key":"10.1002\/14651858.CD005011.pub2-BIB88|cit88","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1111\/j.1445-5994.2007.01472.x","article-title":"Recombinant activated factor VII in critical bleeding: experience from the Australian and New Zealand Haemostasis Register","volume":"38","author":"Isbister","year":"2008","journal-title":"Internal Medicine Journal"},{"key":"10.1002\/14651858.CD005011.pub2-BIB89|cit89","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1423-0410.2008.01063.x","article-title":"Off-label use of recombinant factor VIIa for treatment of haemorrhage: results from randomized clinical trials","volume":"95","author":"Johansson","year":"2008","journal-title":"Vox Sanguinis"},{"key":"10.1002\/14651858.CD005011.pub2-BIB90|cit90","article-title":"Factor VIIa and tissue factor pathway inhibitor","volume-title":"Emerging Technologies in Transfusion Medicine","author":"Key","year":"2003"},{"issue":"12","key":"10.1002\/14651858.CD005011.pub2-BIB91|cit91","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1111\/j.0041-1132.2003.00633.x","article-title":"Recombinant FVIIa for intractable hemorrhage: more questions than answers","volume":"43","author":"Key","year":"2003","journal-title":"Transfusion"},{"key":"10.1002\/14651858.CD005011.pub2-BIB92|cit92","unstructured":"Kruse P Evaluation of safety of activated recombinant FVII as an add-on therapy in spinal surgery Clinicaltrials.gov 2005"},{"key":"10.1002\/14651858.CD005011.pub2-BIB93|cit93","first-page":"211A","article-title":"Recombinant factor VIIa (Novoseven) in partial hepatectomy: a randomized placebo-controlled, double-blinded clinical trial","volume":"36","author":"Lodge","year":"2002","journal-title":"Hepatology"},{"issue":"6","key":"10.1002\/14651858.CD005011.pub2-BIB94|cit94","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1046\/j.1365-2516.1998.00209.x","article-title":"A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. rFVIIa Study Group","volume":"4","author":"Lusher","year":"1998","journal-title":"Haemophilia"},{"issue":"1","key":"10.1002\/14651858.CD005011.pub2-BIB95|cit95","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD004887.pub2","article-title":"Human recombinant activated factor VII for upper gastrointestinal bleeding in patients with liver diseases","author":"Mart\u00ed-Carvajal","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD005011.pub2-BIB96|cit96","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1097\/00005373-200104000-00021","article-title":"Intravenous rFVIIa administered for hemorrhage control in hypothermic coagulopathic swine with grade V liver injuries","volume":"50","author":"Martinowitz","year":"2001","journal-title":"Journal of Trauma"},{"issue":"4","key":"10.1002\/14651858.CD005011.pub2-BIB97|cit97","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1111\/j.1538-7836.2005.01203.x","article-title":"Guidelines for the use of recombinant activated factor VII (rFVIIa) in uncontrolled bleeding: a report by the Israeli Multidisciplinary rFVIIa Task Force","volume":"3","author":"Martinowitz","year":"2005","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD005011.pub2-BIB98|cit98","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/j.1365-2516.2006.01321.x","article-title":"Recombinant factor VIIa in paediatric bleeding disorders - a 2006 review","volume":"12","author":"Mathew","year":"2006","journal-title":"Haemophilia"},{"key":"10.1002\/14651858.CD005011.pub2-BIB99|cit99","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/j.1365-3148.2008.00846.x","article-title":"The evidence for the use of recombinant factor VIIa in massive bleeding: development of a transfusion policy framework","volume":"18","author":"Moltzan","year":"2008","journal-title":"Transfusion Medicine"},{"issue":"12","key":"10.1002\/14651858.CD005011.pub2-BIB100|cit100","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1046\/j.0041-1132.2003.00577.x","article-title":"Recombinant factor VIIa in the management of uncontrolled hemorrhage","volume":"43","author":"O'Connell","year":"2003","journal-title":"Transfusion"},{"issue":"3","key":"10.1002\/14651858.CD005011.pub2-BIB101|cit101","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1001\/jama.295.3.293","article-title":"Thromboembolic adverse events after use of recombinant human coagulation factor VIIa","volume":"295","author":"O'Connell","year":"2006","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD005011.pub2-BIB102|cit102","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s00068-006-6009-1","article-title":"Recombinant factor VIIa for life-threatening hemorrhage in trauma patients: review of the literature","volume":"32","author":"Pape","year":"2006","journal-title":"European Journal of Trauma"},{"key":"10.1002\/14651858.CD005011.pub2-BIB103|cit103","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.2146\/ajhp080008","article-title":"Factor VIIa (recombinant) for acute traumatic hemorrhage","volume":"65","author":"Patanwala","year":"2008","journal-title":"American Journal of Health-System Pharmacy"},{"key":"10.1002\/14651858.CD005011.pub2-BIB104|cit104","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1001\/archsurg.2007.66","article-title":"Efficacy and safety of recombinant activated factor VII in major surgical procedures","volume":"143","author":"Ranucci","year":"2008","journal-title":"Archives of Surgery"},{"key":"10.1002\/14651858.CD005011.pub2-BIB105|cit105","unstructured":"The Nordic Cochrane Centre. The Cochrane Collaboration Review Manager (RevMan) 2008"},{"issue":"Suppl. 12","key":"10.1002\/14651858.CD005011.pub2-BIB106|cit106","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S0037-1963(01)90148-9","article-title":"Recombinant factor VIIa (NovoSeven) and the safety of treatment","volume":"4","author":"Roberts","year":"2001","journal-title":"Seminars in Haematology"},{"issue":"13","key":"10.1002\/14651858.CD005011.pub2-BIB107|cit107","doi-asserted-by":"crossref","first-page":"3858","DOI":"10.1182\/blood-2004-06-2223","article-title":"The use of recombinant factor VIIa in the treatment of bleeding disorders","volume":"104","author":"Roberts","year":"2004","journal-title":"Blood"},{"key":"10.1002\/14651858.CD005011.pub2-BIB108|cit108","unstructured":"Rubinger M Rivard GE Teitel J Walker I Suggestions for the management of hemophiliacs and non-hemophiliacs with factor VIII inhibitors AHCDC Clinical Practice Guidelines, 3rd edition 1999"},{"key":"10.1002\/14651858.CD005011.pub2-BIB109|cit109","unstructured":"Skolnick B Dose response to recombinant factor VIIa when administered for bleed ClinicalTrials.gov"},{"key":"10.1002\/14651858.CD005011.pub2-BIB110|cit110","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2174\/157488607780598278","article-title":"Recombinant activated factor VII as a general haemostatic agent: evidence-based efficacy and safety","volume":"2","author":"Squizzato","year":"2007","journal-title":"Current Drug Safety"},{"key":"10.1002\/14651858.CD005011.pub2-BIB111|cit111","unstructured":"Tillinger M Evaluation of safety and preliminary efficacy of recombinant activated factor VII in subjects with brain contusions ClinicalTrials.gov 2005"},{"key":"10.1002\/14651858.CD005011.pub2-BIB112|cit112","doi-asserted-by":"crossref","first-page":"R14","DOI":"10.1186\/cc6788","article-title":"Recombinant activated factor VIIa for the treatment of bleeding in major abdominal surgery including vascular and urological surgery: a review and meta-analysis of published data","volume":"12","author":"Heymann","year":"2008","journal-title":"Critical Care"},{"key":"10.1002\/14651858.CD005011.pub2-BIB113|cit113","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.athoracsur.2006.10.033","article-title":"Recombinant activated factor VII in cardiac surgery: a systematic review","volume":"83","author":"Warren","year":"2007","journal-title":"Annals of Thoracic Surgery"},{"key":"10.1002\/14651858.CD005011.pub2-BIB114|cit114","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ejvs.2007.08.018","article-title":"Recombinant activated factor VII: a solution to refractory haemorrhage in vascular surgery?","volume":"35","author":"Warren","year":"2008","journal-title":"European Journal of Vascular and Endovascular Surgery"},{"issue":"3","key":"10.1002\/14651858.CD005011.pub2-BIB115|cit115","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005951.pub2","article-title":"Haemostatic drug therapies for acute primary intracerebral haemorrahge","author":"You","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD005011.pub2-BIB116|cit116","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1053\/j.jvca.2008.09.017","article-title":"Recombinant activated factor VII in cardiac surgery: a meta-analysis","volume":"23","author":"Zangrillo","year":"2009","journal-title":"Journal of Cardiothoracic and Vascular Anesthesia"},{"issue":"2","key":"10.1002\/14651858.CD005011.pub2-BIB117|cit117","article-title":"Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia","author":"Stanworth","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["The Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD005011.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T21:43:32Z","timestamp":1628545412000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD005011.pub2"}},"subtitle":[],"editor":[{"given":"Simon","family":"Stanworth","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2007,4,18]]},"references-count":117,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd005011.pub2","relation":{},"subject":[],"published":{"date-parts":[[2007,4,18]]}}}